Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation

Leukemia

Volumn 30, Issue 2, 2016, Pages 285-294

  Radivoyevitch, T ^a   Sachs, R K ^b   Gale, R P ^c   Molenaar, R J ^d,e   Brenner, D J ^f   Hill, B T ^e   Kalaycio, M E ^e   Carraway, H E ^e   Mukherjee, S ^e   Sekeres, M A ^e   Maciejewski, J P ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; COMPUTER PROGRAM; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; SECOND CANCER; ADVERSE EFFECTS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RISK;

FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK;

EID: 84959087767     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.258     Document Type: Article

References (31)

1. Gale RP, Bennett JM, Hoffman FO. Therapy-related AML: a slip of the lip can sink a ship. Leuk Res 2014; 38: 418-420.
2. SEER. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch http://www.seer.cancer.gov, released April 2015, based on the November 2014 submission. 2015.
3. Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, et al. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst 2014; 106: djt462.
4. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897-906.
5. Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. BMC Cancer 2011; 11: 260.
6. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12: 353-360.
7. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121: 2996-3004.
8. Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 2013; 179: 361-382.
9. Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011; 29: 428-434.
10. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivorsPart III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994; 2/1994 137: S68-S97.
11. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
12. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
13. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res 1995; 4: 187-196.
14. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
15. Garwood F. Fiducial limits for the Poisson distribution. Biometrika 1936; 28: 437-442.
16. Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 1988; 18: 91-96.
17. Radivoyevitch T, Ramsey MJ, Tucker JD. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis. Radiat Environ Biophys 1999; 38: 201-206.
18. Tomonaga M. Leukaemia in Nagasaki atomic bomb survivors from 1945 through 1959. Bull World Health Organ 1962; 26: 619-631.
19. Radivoyevitch T, Kozubek S, Sachs RK. Biologically based risk estimation for radiation-induced CML. Inferences from BCR and ABL geometric distributions. Radiat Environ Biophys 2001; 40: 1-9.
20. Radivoyevitch T, Hlatky L, Landaw J, Sachs RK. Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood 2012; 119: 4363-4371.
21. Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 2014; 53: 55-63.
22. Gale RP, Hlatky L, Sachs RK, Radivoyevitch T. Why is there so much therapyrelated AML and MDS and so little therapy-related CML?. Leuk Res 2014; 38: 1162-1164.
23. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N Engl J Med 2014; 37: 2488-2498.
24. Varadarajan R, Ford L, Sait SN, Block AW, Barcos M, Wallace PK, et al. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leuk Res 2009; 33: 1208-1211.
25. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-Analysis. Ann Oncol 2011; 22: 1845-1858.
26. Wallner LP, Wang R, Jacobsen SJ, Haque R. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev 2013; 22: 313-316.
27. Carreras E, Kovats S. Girl power: estrogen promotes HSC self-renewal. Cell Stem Cell 2014; 14: 137-138.
28. Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Saitoh Y, et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature 2014; 505: 555-558.
29. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994; 137: S17-S67.
30. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.